Johnson Johnson

08/04/2014

Hysterectomy Device Recalled Amid Cancer Fears

Johnson & Johnson Hysterectomy Device Recalled

Audet & Partners, LLP reports that Ethicon Endo-Surgery Inc., a unit of Johnson & Johnson, is voluntarily asking doctors to return a device used in performing hysterectomies in thousands of women.  Ethicon's Morcelex device, used in certain laparoscopic surgeries, has come under FDA scrutiny because of the potential of such devices to spread cancerous fibroids. The class of devices known as morcellation devices, which includes Ethicon's Morcelex device, is used in many hysterectomy procedures to break non-cancerous fibroids into smaller fragments... Read More
06/18/2014

Risperdal Off-Label Prescriptions May Expose Johnson & Johnson to Punitive Damages

Risperdal Punitive Damages

Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More
06/18/2014

Risperdal Off-Label Prescriptions May Expose Johnson & Johnson to Punitive Damages

Risperdal Punitive Damages

Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More
05/27/2014

Risperdal Lawsuits Time Barred, Argues Johnson & Johnson

Risperdal Lawsuit Bars Claims for Punitive Damages

Janssen Pharmaceuticals, a division of Johnson & Johnson  that manufactured and marketed the antipsychotic drug Risperdal to adolescent males, asked a Pennsylvania court in a Motion for Summary Judgment dated May 19, 2014, to hold that hundreds of personal injury claims connected to Risperdal administration should be time barred by the applicable statute of limitations.  In its Motion, Janssen has argued that plaintiffs have filed injury claims years, and in some cases, decades after developing a condition called gynecomastia, and... Read More
05/02/2014

Risperdal Class Action FAQs

Risperdal Lawsuit Update

Audet and Partners, LLP is now representing several males who have been diagnosed with Gynecomastia after having taken the antipsychotic drug Risperdal.  If you have suffered this or a similar injury, you may be wondering whether you may have a valid claim for damages. The FAQs below are intended to better help you understand and assess how you might proceed in bringing a Risperdal lawsuit. (1) What is the basis for the current Risperdal lawsuits against Johnson & Johnson? For over a decade,... Read More
04/16/2014

Whistleblower Lawsuits On The Rise

Whistleblower Award

Whistleblower claims, or "qui tam" lawsuits, brought under the federal False Claims Act, increased to 753 in 2013, an increase of almost 20% over the previous year.*  These claims resulted in aggregate net recoveries to the federal government of $3.8 billion last year.  For the past four years, whistleblower lawsuits have produced recoveries to the federal government exceeding an aggregate amount of $3 billion. What is driving the rise in whistleblower lawsuits under the False Claims Act?  False claims involving healthcare... Read More
04/09/2014

Transvaginal Mesh Litigation Update: Consumer Group Calls for Criminal Investigation into Johnson & Johnson Destruction of Evidence

Transvaginal Mesh Lawsuits

In follow up to Audet & Partners, LLP previous reports on Johnson & Johnson’s alleged systematic destruction of documents related to the safety of its vaginal mesh products, a consumer advocacy group has asked the United States Department of Justice to launch a criminal investigation in hopes that it will result in holding the company accountable for any misdeeds. According to reports, the Corporate Action Network, a consumer advocacy group, has asked Attorney General Eric Holder to investigate whether or not... Read More
03/25/2014

Risperdal Lawsuit $1.2 Billion Verdict Overturned by Arkansas Supreme Court

Risperdal Lawsuit News

On March 20, 2014, the Arkansas Supreme Court overturned a trial court award of $1.2 billion to the State of Arkansas against Johnson & Johnson, and its Janssen Pharmaceuticals, Inc. division based on the company's marketing of the antipsychotic frog Risperdal.  This Arkansas lawsuit had been brought by the Arkansas Attorney General and relied on a provision of Arkansas state law governing Medicaid fraud as a basis to challenge the marketing of Risperdal in Arkansas which allegedly included misleading claims... Read More
03/12/2014

Risperdal Lawsuit Settlement Costs Johnson & Johnson $5.9 Million

Risperdal Lawsuits

Janssen Pharmaceutical, Inc., the division of Johnson & Johnson that developed and marketed the Risperdal antipsychotic medication, has settled a Risperdal lawsuit brought by the State of Montana for $5.9 million.  The Attorney General of Montana had initiated a lawsuit against the manufacturer in 2008 alleging that the company promoted the drug as safe despite having knowledge of a range of dangerous side effects, including diabetes. The settlement terms require Johnson & Johnson to cease any misleading marketing of Risperdal, and... Read More
03/11/2014

Risperdal Lawsuits Stress Demonstrated Link to Enlarged Breast Tissue in Males

Risperdal Lawyers

Audet & Partners, LLP is investigating claims for serious personal injuries, including breast enlargement in males, tied to administration of the antipsychotic drug Risperdal.  Commonly prescribed to treat schizophrenia and bipolar disorder, and occasionally used off-label to address ADHD, Risperdal has been shown in several studies over the past fifteen years to be strongly linked to elevated levels of prolactin in males, a hormonal precursor to breast development and lactation in women. This condition, referred to as Risperdal Gynecomastia, is irreversible.... Read More
01/09/2014

Transvaginal Mesh Litigation Reveals Possible Widespread Document Destruction by Johnson & Johnson

According to recently filed court documents, Johnson & Johnson officials systematically destroyed or lost documents relating to its vaginal mesh implants despite having been ordered to preserve that evidence. Bloomberg.com reported* the alleged document destruction in early December 2013 after court documents were filed by the attorneys representing women who have sued Johnson & Johnson over injuries associated with the transvaginal mesh devices.  Destruction of critical evidence may potentially hinder the prosecution of valid transvaginal mesh claims by affected women.  The... Read More
08/28/2013

Hip Implant Litigation Against Johnson & Johnson Reportedly Closer To Settlement

metal-hip-implant-litigation-update

Johnson and Johnson, the manufacturers of certain defective artificial hips may be near settling with a large number of plaintiffs in coming weeks.* If the pharmaceutical company pays the purported $3 billion reported in the media, this will double the amount it had thus far been willing to offer to settle the lawsuits against it.* Both sides have an interest in settling the claims as multiple test trials are set for the coming months.* Between the months of September and... Read More